Sepracor Licenses Late-Stage Anti-Epileptic From Portuguese Pharma Bial
This article was originally published in The Pink Sheet Daily
Executive Summary
Late 2008/early 2009 NDA filing targeted for the new chemical entity as an adjunct therapy to improve control of epileptic seizures.
You may also be interested in...
Sunovion Sees Advantage For Aptiom As Unscheduled Epilepsy Drug
Dainippon subsidiary plans to launch its next-generation version of carbamazepine in the second half of 2014. Lack of classification as a controlled substance means more direct access to prescribers, company says.
Sepracor To Meet With FDA After Complete Response Letter For Epilepsy Drug Stedesa
Agency had extended the review of the seizure therapy by three months, but still needs additional information.
Sepracor To Meet With FDA After Complete Response Letter For Epilepsy Drug Stedesa
Agency had extended the review of the seizure therapy by three months, but still needs additional information.